Recombinant ASFV I267L Protein, N-GST

Description of Recombinant ASFV I267L Protein, N-GST

Introduction to Recombinant ASFV I267L Protein

The African swine fever virus (ASFV) is a highly contagious and deadly virus that affects domestic pigs and wild boars. It is responsible for significant economic losses in the pig farming industry and poses a threat to food security. In recent years, there has been a growing interest in developing effective vaccines against ASFV. One promising approach is the use of recombinant proteins, such as the ASFV I267L protein, as antigens in vaccine formulations.

Structure of Recombinant ASFV I267L Protein

The ASFV I267L protein is a 267 amino acid long protein that is encoded by the I267L gene of the ASFV genome. It is a transmembrane protein that is present on the surface of the virus particle. The protein has a predicted molecular weight of approximately 30 kDa and contains several conserved domains, including a signal peptide, a transmembrane domain, and a cytoplasmic tail.

The crystal structure of the ASFV I267L protein has been recently determined, revealing a trimeric structure with a central coiled-coil region and three globular domains at the N-terminus. This trimeric structure is important for the protein’s function as an antigen, as it allows for the formation of stable complexes with other viral proteins and efficient recognition by the immune system.

Activity of Recombinant ASFV I267L Protein

The ASFV I267L protein plays a crucial role in the virus’s ability to evade the host’s immune response. It is involved in the inhibition of the host’s immune system by interfering with the production and function of cytokines, which are important molecules for triggering an immune response. The protein also interacts with host cell receptors, allowing the virus to enter and infect the cells.

As a recombinant protein, the ASFV I267L protein can be produced in large quantities using recombinant DNA technology. This allows for the production of a highly pure and consistent antigen, which is essential for the development of effective vaccines. The protein can also be modified to enhance its activity and stability, making it a promising candidate for vaccine development.

Application of Recombinant ASFV I267L Protein

The recombinant ASFV I267L protein has been shown to induce a strong immune response in pigs, making it a promising antigen for vaccine development. Several studies have demonstrated its efficacy in protecting pigs against ASFV infection, either alone or in combination with other viral proteins.

One study showed that vaccination with a recombinant ASFV I267L protein-based vaccine resulted in complete protection against a lethal dose of ASFV in pigs. Another study found that pigs vaccinated with a combination of the ASFV I267L protein and another viral protein had a significantly lower viral load and milder clinical signs upon ASFV infection compared to unvaccinated pigs.

In addition to its potential as a vaccine antigen, the recombinant ASFV I267L protein has also been used for diagnostic purposes. It has been shown to be highly specific and sensitive in detecting ASFV antibodies in infected pigs, making it a valuable tool for disease surveillance and control.

Conclusion

The recombinant ASFV I267L protein is a promising antigen for the development of vaccines against ASFV. Its unique structure, activity, and application make it a valuable tool in the fight against this devastating virus. Further research and development of this protein could lead to the development of effective vaccines that can protect pigs and prevent the spread of ASFV.